Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

BACKGROUND:Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome. We explored outcomes stratified by diabetes mellitus (DM). METHODS:In IMPROVE-IT (Improved Reduction of OutcomesVytorin Efficacy International Trial), 18 144 patients after acute coronary sy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2018-04, Vol.137 (15), p.1571-1582
Hauptverfasser:	Giugliano, Robert P, Cannon, Christopher P, Blazing, Michael A, Nicolau, José C, Corbalán, Ramón, Špinar, Jindřich, Park, Jeong-Gun, White, Jennifer A, Bohula, Erin A, Braunwald, Eugene
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - diagnosis Acute Coronary Syndrome - mortality Acute Coronary Syndrome - therapy Aged Biomarkers - blood Cholesterol, LDL - blood Comorbidity Diabetes Mellitus - diagnosis Diabetes Mellitus - mortality Diabetes Mellitus - therapy Dyslipidemias - diagnosis Dyslipidemias - drug therapy Dyslipidemias - mortality Ezetimibe, Simvastatin Drug Combination - adverse effects Ezetimibe, Simvastatin Drug Combination - therapeutic use Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Middle Aged Risk Assessment Risk Factors Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!